NuCana plc ADR (NCNA)
NASDAQ: NCNAHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
NCNA stock chart
Technical analysisKey statistics
All statistics- Market cap
- $3.61M
- EPS (TTM)
- $0.00
- Dividend yield
- None
- 52-week range
- 0.62 – 4.55
- Day range
- 0.7026 – 0.7899
- Volume / Avg
- 25.52K / 118.13K
- Beta
- —
- Shares outstanding
- 4.82M
52-week range
NCNA stock today
NuCana (NCNA) closed at $0.7495 on Nov 20, up 4.39% (+$0.0315), versus the S&P 500's 3.70% decline. Trading was light, with 25.52K shares changing hands, about 22% of the average daily volume. At this level, NCNA sits near the bottom of its 52-week range of $0.62 to $4.55: 83.5% below the high and 20.9% above the low.
NuCana has posted a net loss over the last twelve months (EPS of $0.00), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About NuCana
Company profileNuCana plc, a clinical-stage biopharmaceutical company, engages in the development of medicines to treat patients with cancer in the United States. It applies its ProTide technology to transform prescribed chemotherapy agents and nucleoside analogs into medicines. The company is developing medicines to overcome the limitations of nucleoside analogs and generate concentrations of anti-cancer metabolites in cancer cells.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Mr. Hugh Stephen Griffith
- Headquarters
- Edinburgh
- Employees
- 10
- IPO year
- 2017
- Website
- nucana.com
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 12, 2026
- EPS actual vs est.
- $-0.10 vs —
NCNA news
All NCNA news- NuCana's NUC-7738 Enhances Carfilzomib Activity In Multiple Myeloma TreatmentNasdaqNCNA, UHAL.B
- NuCana plc Announces Preclinical Data Showing NUC-7738 Enhances Carfilzomib ActivityNasdaqNCNA, SUN
- NuCana Presents Preclinical Data Showing NUC-7738 Enhances Carfilzomib Activity in Multiple Myeloma Cell Lines at the 38th EORTC-NCI-AACR SymposiumGlobeNewswire
- NuCana Reports Third Quarter 2026 Financial Results and Provides Business UpdateGlobeNewswire
NuCana peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| BGMSBio Green Med Solution Inc. | 0.553 | -9.48% | $3.66M | vs NCNA |
| SILOSilo Pharma Inc. | 1.71 | -9.04% | $3.69M | vs NCNA |
| ALZNAlzamend Neuro Inc. | 0.7758 | -23.94% | $3.74M | vs NCNA |
| IMNNImunon Inc. | 0.5355 | -5.22% | $3.47M | vs NCNA |
| XTLBXTL Biopharmaceuticals Ltd. ADR | 1.37 | -5.84% | $3.37M | vs NCNA |
| LTRNLantern Pharma Inc. | 0.245 | -13.73% | $3.89M | vs NCNA |
| XBIOXenetic Biosciences Inc. | 1.40 | -9.09% | $3.28M | vs NCNA |
| APREAprea Therapeutics Inc. | 0.229 | -53.56% | $3.25M | vs NCNA |
Indexes, lists and sector
NuCana stock FAQ
What is NuCana's stock price today?
NCNA last traded at $0.7495 as of Nov 20, 4:00 PM EST, up 4.39% on the day. Prices are delayed at least 15 minutes.
Who is NuCana's CEO?
Mr. Hugh Stephen Griffith is the chief executive officer of NuCana plc ADR, which has about 10 employees.
What is the NCNA 52-week high?
The 52-week high for NCNA is $4.55 and the 52-week low is $0.62. The stock is currently 83.5% below its high.